Rethinking Global and Local Manufacturing of Medical Products After COVID-19
SpringerBriefs Public Health
; : 39-58, 2022.
Artículo
en Inglés
| EMBASE | ID: covidwho-1623258
ABSTRACT
The unprecedented global health crisis caused by the coronavirus (COVID-19) pandemic since the first quarter of 2020 has reopened the now-urgent discussion about the role of local pharmaceutical production in addressing the health needs in developing countries. The COVID-19 crisis has highlighted the interdependencies in the global production of pharmaceuticals – no country is self-sufficient. Many industrialised countries are making the decision to repatriate or initiate the production of active pharmaceutical ingredients (APIs) and medicines. Governments are beginning to talk about ‘pharmaceutical sovereignty’ or ‘health security’. If this becomes a reality and the production of pharmaceuticals is led by nationalistic policies, developing countries that still lack manufacturing capacity will have to start or expand the local production of pharmaceuticals, whether at the national or regional level. The war to get access to the future vaccine for COVID-19 does not look easy with these new developments.
Texto completo:
Disponible
Colección:
Bases de datos de organismos internacionales
Base de datos:
EMBASE
Idioma:
Inglés
Revista:
SpringerBriefs Public Health
Año:
2022
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS